Incidence of cardiovascular disease-related events and all-cause hospitalisations associated with exenatide versus insulin, thiazolidinediones, sulfonylureas, metformin and sitagliptin in patients with type 2 diabetes mellitus.

Trial Profile

Incidence of cardiovascular disease-related events and all-cause hospitalisations associated with exenatide versus insulin, thiazolidinediones, sulfonylureas, metformin and sitagliptin in patients with type 2 diabetes mellitus.

Completed
Phase of Trial: Phase IV

Latest Information Update: 18 Nov 2010

At a glance

  • Drugs Exenatide; Insulin; Metformin; Sitagliptin; Sulfonylureas; Thiazolidinediones
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions
  • Sponsors Amylin Pharmaceuticals; Eli Lilly
  • Most Recent Events

    • 18 Nov 2010 New trial record
    • 17 Nov 2010 Results were presented at the American Heart Association 2010 Scientific Sessions, according to an Amylin Pharmaceuticals and Eli Lilly media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top